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Abstract
Despite its potent ability to inhibit proinflammatory cytokine
synthesis, interleukin (IL)-10 has a marginal clinical effect in
rheumatoid arthritis (RA) patients. Recent evidence suggests
that IL-10 induces monocyte/macrophage maturation in
cooperation with macrophage-colony stimulating factor (M-
CSF). In the present study, we found that the inducible subunit
of the IL-10 receptor (IL-10R), type 1 IL-10R (IL-10R1), was
expressed at higher levels on monocytes in RA than in healthy
controls, in association with disease activity, while their
expression of both type 1 and 2 tumour necrosis factor
receptors (TNFR1/2) was not increased. The expression of IL-
10R1 but not IL-10R2 was augmented on monocytes cultured
in the presence of RA synovial tissue (ST) cell culture
supernatants. Cell surface expression of TNFR1/2 expression
on monocytes was induced by IL-10, and more efficiently in
combination with M-CSF. Two-color immunofluorescence
labeling of RA ST samples showed an intensive coexpression of
IL-10R1, TNFR1/2, and M-CSF receptor in CD68+  lining
macrophages. Adhered monocytes, after 3-day preincubation
with IL-10 and M-CSF, could produce more IL-1β and IL-6 in
response to TNF-α in the presence of dibutyryl cAMP, as
compared with the cells preincubated with or without IL-10 or
M-CSF alone. Microarray analysis of gene expression revealed
that IL-10 activated various genes essential for macrophage
functions, including other members of the TNFR superfamily,
receptors for chemokines and growth factors, Toll-like
receptors, and TNFR-associated signaling molecules. These
results suggest that IL-10 may contribute to the inflammatory
process by facilitating monocyte differentiation into TNF-α-
responsive macrophages in the presence of M-CSF in RA.
Introduction
Macrophages play an important role in both chronic inflamma-
tion and joint destruction in rheumatoid arthritis (RA), princi-
pally by producing many proinflammatory cytokines such as
tumour necrosis factor-α (TNF-α) [1]. The significance of TNF-
α in the pathogenesis has been well proven by the clinical effi-
cacy of its blockade in RA patients with active disease [2]. The
pleiotropic effects of TNF-α are mediated through two distinct
TNF receptors, the type 1 p60/p55 receptor (TNFR1) and the
type 2 p80/p75 receptor (TNFR2) [3,4]. TNFR1 is expressed
in all cell types and activates various cellular responses
through the transcription factor NF (nuclear factor)-κB and
apoptosis [5-7]. In contrast, TNFR2 is expressed by cells of
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the immune system and endothelial cells, and its precise role
is less clear [7,8]. However, TNFR2 mediates part of TNF
effects, including proliferation of T cells and B cells, NF-κB
activation, and cytotoxicity, and may potentiate the effects of
TNFR1 by ligand passing to the lower-affinity TNFR1 [9,10].
Interleukin (IL)-10 has been recognised as a key cytokine that
modulates the cell-mediated immune response by regulating
activation and effector function of T cells and monocytes/mac-
rophages, most notably by inhibiting the production of
cytokines such as TNF-α, IL-1, IL-6, and interferon-γ [11]. IL-
10 binds to the IL-10 receptor (IL-10R) complex composed of
two subunits, the primary ligand-binding component IL-10R1
and the accessory component IL-10R2. IL-10R2 is constitu-
tively expressed, but IL-10R1 is inducible; IL-10R1 thus seems
critical in the IL-10-mediated cellular response [11]. Interest-
ingly, TNF-α effectively induces IL-10 synthesis in monocytes,
which represents the major negative feedback to its own pro-
duction [12]. In the synovial tissue (ST) of RA, high levels of IL-
10 are expressed in the lining layer and mononuclear cell
aggregates, presumably in response to TNF-α overproduction
[13,14]. However, such IL-10 induction may be insufficient to
regulate proinflammatory cytokine expression in RA, because
the addition of exogenous IL-10 to ST cell cultures markedly
reduced TNF-α and IL-1 production [13,15]. These findings
suggested the possibility of its therapeutic application in this
inflammatory arthritis [16].
In various animal models of arthritis, IL-10 reduced joint swell-
ing, cellular infiltration, cytokine production, and cartilage deg-
radation when administered to animals either before or after
induction of disease [16,17]. However, clinical studies per-
formed so far have shown that human recombinant IL-10 (rIL-
10) has little therapeutic efficacy in patients with RA [16-18].
Accordingly, immunohistochemical analysis of serial synovial
biopsies from the patients treated with IL-10 showed no sig-
nificant change in inflammatory cell infiltration and expression
of TNF-α, IL-1β, and IL-6 after treatment [19]. Thus, IL-10
appears to play a dual role as inhibitor and stimulator in human
joint inflammation. In fact, the expression of Fcγ receptor type
I (FcγRI; CD64) and FcγRII (CD32) on circulating monocytes
was enhanced after IL-10 treatment in patients with RA, and
the in vitro study showed that IL-10-primed monocytes with
high-level expression of FcγRI and FcγRII are able to produce
TNF-α in response to immune complexes [18]. In addition, IL-
10 stimulates cell surface expression of TNFR2 on RA synovial
fluid macrophages, and it enhances the TNF-α effect on IL-1β
production by monocytes by increasing surface receptor lev-
els [20]. These findings indicate that IL-10 may contribute to
monocyte differentiation into the proinflammatory type of mac-
rophages characteristic of RA.
It has been shown that IL-10 augments the macrophage col-
ony-stimulating factor (M-CSF)-induced growth and differenti-
ation of human monocytes, and macrophages generated in
that manner show reactive oxygen intermediate and IL-6 pro-
duction and Fcγ-mediated phagocytosis more prominently
than macrophages generated by M-CSF alone [21]. We have
previously shown that CD16 (FcγRIIIA)-expressing monocytes
and ST macrophages with high expression of Toll-like receptor
(TLR) 2 may be induced by IL-10 and M-CSF and that their
TNF-α production could be stimulated by endogenous ligands
such as Hsp 60 and immune complexes in RA joints [22,23].
To elucidate the role of IL-10 in monocyte differentiation into
TNF-α-responsive tissue macrophages, we investigated the
expression and regulation of receptors for IL-10, M-CSF, and
TNF-α in blood monocytes and ST macrophages from patients
with RA.
Table 1
Demographic and clinical data of patients with rheumatoid arthritis
Low activitya (n = 4) Moderate activity (n = 13) High activity (n = 13)
Age (years) 55.2 ± 8.0b 55.0 ± 4.5 59.1 ± 2.9
Gender (men/women) 1/3 3/10 2/11
Disease duration (years) 1.3 ± 0.2 6.6 ± 1.4 4.5 ± 3.0
Tender joint count 0.3 ± 0.3 2.5 ± 0.5 10.0 ± 2.2
Swollen joint count 0.0 ± 0.0 3.2 ± 0.9 10.5 ± 2.0
ESR (mm/hour) 21.5 ± 7.3 43.5 ± 6.0 67.7 ± 8.7
CRP (mg/liter) 10.1 ± 6.9 9.2 ± 1.8 47.7 ± 9.3
Rheumatoid factor (units/ml) 145 ± 106 138 ± 53 203 ± 62
Visual analogue scale (mm) 8 ± 5 30 ± 6 57 ± 7
DAS28 2.3 ± 0.4 4.2 ± 0.2 6.1 ± 0.2
aDivided into patient groups with low (<3.2), moderate (3.2–5.1), and high disease activity (>5.1) according to the 28-joint disease activity score 
(DAS28). bMean ± standard error. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.Available online http://arthritis-research.com/content/8/4/R126
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Materials and methods
Patients and samples
The total patient population consisted of 30 patients with RA
(24 women and 6 men; mean ± standard deviation age, 57.2
± 13.6 years) diagnosed according to the revised 1987 crite-
ria of the American College of Rheumatology (formerly, the
American Rheumatism Association) [24]. Patients were
receiving prednisolone (≤ 7.5 mg/day; n = 22) and disease-
modifying antirheumatic drugs such as methotrexate (n = 12)
and salazosulfapyridine (n = 8). They were divided into groups
with low, moderate, and high disease activity using the 28-joint
disease activity score (DAS28) system [25]; the demographic
and laboratory data in these three groups are shown in Table
1. Twenty-six healthy volunteers (20 women and 6 men)
matched for age (58.8 ± 15.5 years) served as controls. ST
samples were obtained from five patients with RA (4 women
and 1 man; age 61.6 ± 3.5 years; disease duration 14.0 ± 2.0
years) at the time of total knee joint replacement. Their clinical
parameters were as follows: tender joint count (0–28), 4.2 ±
1.1; swollen joint count (0–28), 2.8 ± 1.5; erythrocyte sedi-
mentation rate, 49 ± 6 mm/hour; serum C-reactive protein, 22
± 5 mg/liter; immunoglobulin (Ig) M class rheumatoid factor
(RF) titer, 61 ± 17 units per ml; visual analogue scale, 40 ± 3
mm; and DAS28, 4.7 ± 0.1. All patients gave informed con-
sent.
Flow cytometry
Peripheral blood mononuclear cells (PBMCs) were prepared
from heparinised blood samples by centrifugation over Ficoll-
Hypaque density gradients (Pharmacia, Uppsala, Sweden).
Cells were washed well with RPMI 1640 medium (Invitrogen,
Carlsbad, CA, USA) and were resuspended in phosphate-
buffered saline (PBS) with 1% heat-inactivated fetal calf
serum (FCS) (Invitrogen). Cell surface expression of IL-10R1,
IL-10R2, M-CSF receptor (M-CSFR), TNFR1, and TNFR2 was
analysed by cell surface staining and flow cytometry as
described previously [22,23]. PBMC suspensions were incu-
bated with mouse IgG1  anti-IL-10R1 monoclonal antibody
(mAb) (R&D Systems, Minneapolis, MN, USA), mouse IgG1
anti-IL-10R2 mAb (R&D Systems), rabbit IgG anti-M-CSFR (c-
fms) polyclonal Ab (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA), mouse IgG2a anti-TNFR1 mAb (BD Bio-
sciences, San Jose, CA, USA), fluorescein isothiocyanate
(FITC)-conjugated mouse IgG2a anti-TNFR2 mAb (Genzyme/
Techne, Minneapolis, MN, USA), or isotype-matched control
Abs. Cells were washed and then incubated with rhodamine-
conjugated goat anti-mouse IgG1 mAb (Santa Cruz Biotech-
nology, Inc.) for anti-IL-10R1 mAb and anti-IL-10R2 mAb, phy-
coerythrin-conjugated goat anti-rabbit IgG mAb (Santa Cruz
Biotechnology, Inc.) for anti-M-CSF Ab, or FITC-conjugated
anti-mouse IgG2a mAb (Santa Cruz Biotechnology, Inc.) for
anti-TNFR1 mAb. After washing, cells were resuspended in
1% FCS/PBS. Analysis was performed on a FACScan flow
cytometer (BD Biosciences). The monocytes were specifically
analysed by selective gating based on parameters of forward
and side light scatter. By flow cytometric analysis of PBMCs
with anti-CD14 mAb (Becton, Dickinson and Company, Fran-
klin Lakes, NJ, USA), the scattered light-based monocyte pop-
ulation from three patients with RA and three healthy controls
was found to contain more than 93% of CD14+ cells, and
there was no significant difference in their CD14+ cell frequen-
cies.
Isolation and culture of blood monocytes
PBMCs were resuspended at a density of 5 × 106 cells in cul-
ture medium (RPMI 1640 medium supplemented with 25 mM
HEPES, 2 mM L-glutamine, 2% nonessential amino acids, 100
U/ml penicillin, and 100 µg/ml streptomycin) with 10% FCS.
Monocytes were purified from PBMCs by negative selection
using a cocktail of Abs against CD3, CD7, CD16, CD19,
CD56, CD123, and glycophorin A (monocyte isolation kit II;
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) accord-
ing to the manufacturer's instructions. The cell suspensions
were adjusted at a density of 5 × 105 cells per ml in culture
medium with 10% FCS and were incubated with or without
20% RA ST cell culture supernatants, 25 ng/ml human rIL-10
(R&D Systems), 50 ng/ml human rM-CSF (R&D Systems), or
rIL-10 plus rM-CSF in the wells of 48-well plates (Ultra Low
Attachment Clusters; Corning Incorporated, Corning, NY,
USA) in a humidified atmosphere containing 5% CO2. Three
days later, the cells were harvested, and cell surface expres-
sion of cytokine receptors was determined by flow cytometric
analysis.
In addition, monocytes were preincubated with or without 25
ng/ml rIL-10, 50 ng/ml rM-CSF, or rIL-10 plus rM-CSF, and
the cells were washed with culture medium and were incu-
bated at a density of 5 × 104 cells per 200 µl in 96-well plates
(Corning Incorporated) with or without 10 ng/ml human rTNF-
α (Sigma-Aldrich, St. Louis, MO, USA), 30 µM N6,2'-O-dibu-
tyryladenosine-3'-5'-cyclic monophosphate sodium (dbcAMP)
(BIOMOL International, L.P., Exeter, UK), or rTNF-α plus
dbcAMP. Twenty-four hours later, cell-free culture superna-
tants samples were stored at -30°C until the cytokine assay.
To determine IL-10-induced mRNA expression of cytokine
receptors, PBMC suspensions were incubated in six-well
plates (Corning Incorporated) at 37°C for 2 hours, and adher-
ent monocytes, after removal of nonadherent cells, were gently
harvested using a rubber spatula; the purity of monocytes was
found to be more than 95%, as determined by flow cytometric
analysis of CD14 and CD3 expression. The cells suspensions,
adjusted at a density of 5 × 105 cells per ml in culture medium
with 10% FCS, were incubated with or without 25 ng/ml rIL-
10. Twelve hours later, the cells were immediately lysed using
a reagent for RNA isolation (TRIzol reagent; Invitrogen) and
were stored at -80°C until RNA isolation.
RA ST cell culture supernatants were prepared as previously
described [26]. Briefly, ST samples from patients with RAArthritis Research & Therapy    Vol 8 No 4    Takasugi et al.
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were fragmented and digested with collagenase and DNase
for 1 hour at 37°C. After tissue debris was removed, cells were
resuspended in culture medium with 10% FCS. RA ST cells
were incubated at a density of 1 × 106 cells per ml in 10%
FCS/culture medium in six-well plates; 72 hours later, culture
supernatants were harvested and stored at -30°C.
RNA isolation and real-time polymerase chain reaction
Total cellular RNA was extracted from adhered monocytes
lysed in TRIzol reagent according to the manufacturer's
instructions. Complementary DNA (cDNA) was synthesised
from total RNA with Molony murine leukemia virus reverse tran-
scriptase (USB Corporation, Cleveland, OH, USA) and oligo-
(dT)15 primers (Promega Corporation, Madison, WI, USA). To
semiquantify the amounts of TNFR1 and TNFR2 mRNAs, real-
time polymerase chain reaction (PCR) was performed with the
LightCycler Instrument (Roche Diagnostics, Penzberg, Ger-
many) in glass capillaries. The reaction mix containing DNA
double-strand-specific SYBR green I dye (Roche Diagnostics)
and specific primers for human TNFR1 and TNFR2 (Nihon
Gene Research Laboratories, Sendai, Japan) and β-actin
(Search-LC GmbH, Heidelberg, Germany) were added to
cDNA dilutions. The cDNA samples were amplified and ana-
lysed according to the manufacture's instructions. TNFR1 and
TNFR2 expression was determined by normalisation against
β-actin expression. The sequences of oligonucleotide primers
were as follows: for TNFR1, 5' primer GGT GAC TGT CCC
AAC TTT GC and 3' primer GGG TCA TCA GTG TCT AGG
CT 3'; for TNFR2, 5' primer CTT CGC TCT TCC AGT TGG
and 3' primer AGG CAA GTG AGG CAC CTT.
Immunoassays for IL-1β and IL-6
Concentrations of IL-1β and IL-6 in monocyte culture superna-
tants were measured in triplicate by the quantitative sandwich
enzyme-linked immunosorbent assay (ELISA) using cytokine-
specific capture and biotinylated detection mAbs and recom-
binant cytokine proteins (all from BD Biosciences) according
to the manufacturer's protocol. The detection limits for these
cytokines were 7.8 pg/ml.
Two-color immunofluorescence labeling
Cryostat sections (4 µm) from RA ST samples were fixed in
acetone and blocked with 10% rabbit or goat serum for 30
minutes. Double immunofluorescence was performed by seri-
ally incubating sections with 10 µg/ml of mouse IgG1 anti-IL-
10R1 mAb, rabbit IgG anti-TNFR1 Ab, rabbit IgG anti-TNFR2
Ab (Santa Cruz Biotechnology, Inc.), rabbit IgG anti-M-CSFR
Ab, mouse IgG1 anti-CD68 mAb (BD Biosciences), and iso-
type-matched control Abs at 4°C overnight, followed by incu-
bation with rhodamine-conjugated goat anti-mouse IgG1 mAb
(Santa Cruz Biotechnology, Inc.) and FITC-conjugated anti-
rabbit IgG mAb (Santa Cruz Biotechnology, Inc.) for 30 min-
utes at room temperature. The double immunofluorescence of
sections was examined with an LSM510 inverted laser-scan-
ning confocal microscope (Carl Zeiss, Jena, Germany) and illu-
minated with 488 nm and 568 nm of light. Images decorated
with FITC and rhodamine were recorded simultaneously
through separate optical detectors with a 530 nm band-pass
filter and a 590 nm long-pass filter, respectively. Pairs of
images were superimposed for colocalisation analysis.
Microarray analysis of gene expression
IL-10-induced gene expression profiles in monocytes were
determined by microarray analysis using the gene expression
array kit (SuperArray Bioscience Corporation, Frederick, MD,
USA), which detects 367 known genes that encode for inflam-
matory cytokines, chemokines and their receptors, and cell
surface markers, as well as representative signaling proteins
and downstream targets of the signal transduction pathways
that mediate the immune response. RNA preparation, probe
synthesis, hybridisation, chemiluminescent detection, and
image and data acquisition and analysis were performed
according to the manufacture's protocol. All signal intensities
of the genes were normalised to those of β-actin.
Statistical analysis
Samples with values below the detection limit for the assay
were regarded as negative and assigned a value of zero. Data
were expressed as the mean ± standard error of the mean. The
statistical significance of differences between two groups was
determined by the Mann-Whitney U test. P < 0.05 was con-
sidered significant. The correlation coefficient was obtained by
Spearman's rank correlation test.
Results
Increased expression of IL-10R1 in blood monocytes 
from patients with active RA
The IL-10 receptor is a heterodimer consisting of two subunits,
and expression of the inducible IL-10R1 seems critical in cel-
lular responses to IL-10 [11]. The cell surface expression of IL-
10R1 and IL-10R2 on peripheral blood monocytes from
patients with RA and healthy controls was determined by flow
cytometric analysis. Figure 1a shows representative histo-
graphic patterns of IL-10R1 expression on monocytes. The
mean fluorescence intensity (MFI) ratio of IL-10R1 was signif-
icantly higher in patients with RA than in controls (RA 2.92 ±
0.42, n = 30; controls 1.93 ± 0.16, n = 25; P < 0.05), but the
MFI ratio of IL-10R2 was lower in patients with RA (RA 8.26 ±
0.59; controls 11.81 ± 0.94; P < 0.01). To determine the cor-
relation of IL-10R1 levels and disease activity, we divided
patients with RA into three groups according to disease activ-
ity using the DAS28 system – low activity (DAS28 < 3.2),
moderate activity (3.2–5.1), and high activity (>5.1) – and
compared the IL-10 R1 intensity of monocytes from these RA
groups and controls. As shown in Figure 1b, the levels of IL-
10R1 expression incrementally increased in patients with RA
with higher disease activity. However, IL-10R1 levels did not
correlate with patients' age, disease duration, or the drug ther-
apy employed. These results indicate that RA blood mono-Available online http://arthritis-research.com/content/8/4/R126
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cytes may become responsive to IL-10 during active disease
in terms of receptor expression.
IL-10R1 induction in monocytes by RA ST cell culture 
supernatants
To corroborate the correlation between the high expression of
IL-10R1 on monocytes and disease activity, purified mono-
cytes were incubated for 3 days with or without 20% RA ST
cell culture supernatants, and the induction of cell surface IL-
10R1 and IL-10R2 was determined by flow cytometry. Figure
2 shows the ratio of the MFI of IL-10R1 and IL-10R2 expres-
sion with culture supernatants to the MFI with culture medium
alone. The levels of IL-10R1, but not IL-10R2, were signifi-
cantly augmented in the presence of culture supernatants.
These results indicate that the increased IL-10R1 on mono-
cytes found in active RA may be induced by a spillover effect
of the particular stimuli produced in the inflamed joint, such as
cytokines.
Expression of TNFR1, TNFR2, and M-CSFR in RA blood 
monocytes
To examine whether the expression of two distinct receptors
for TNF-α, TNFR1 and TNFR2, and of M-CSFR was also
increased in RA monocytes, the cell surface expression of
these receptors on blood monocytes from patients with RA
and healthy controls was determined by flow cytometry. As
shown in Figure 3, there was no significant difference in
TNFR1 expression between patients with RA and controls;
Figure 1
Expression of type 1 interleukin-10 receptor (IL-10R1) on monocytes  from patients with rheumatoid arthritis (RA) Expression of type 1 interleukin-10 receptor (IL-10R1) on monocytes 
from patients with rheumatoid arthritis (RA). (a) Representative histo-
graphic patterns of IL-10R1 expression on monocytes of patients with 
RA and healthy controls (HCs). Peripheral blood mononuclear cells 
were stained with mouse immunoglobulin (Ig) G1 anti-IL10R1 antibody 
or isotype-matched control antibody, followed by fluorescein isothiocy-
anate-conjugated goat anti-mouse IgG1 antibody. Flow cytometric anal-
ysis of IL-10R1 expression was performed by gating on monocytes 
according to light scatter profile. (b) Increased IL-10R1 expression on 
monocytes from RA patients with active disease. Patients with RA were 
divided into groups with low, moderate, and high disease activity 
according to the disease activity score 28 (DAS28) system. The inten-
sity of cell surface IL-10R1 expression on monocytes from RA patients 
and HCs was expressed by the ratio of the mean fluorescence intensity 
(MFI) of staining with anti-IL-10R1 antibody to the MFI of control anti-
body. Values are the mean ± standard error of the mean. n, number of 
samples tested.
Figure 2
Induction of monocyte expression of type 1 and type 2 interleukin-10  receptor (IL-10R1/2) by culture supernatants of rheumatoid arthritis  (RA) synovial tissue (ST) cells Induction of monocyte expression of type 1 and type 2 interleukin-10 
receptor (IL-10R1/2) by culture supernatants of rheumatoid arthritis 
(RA) synovial tissue (ST) cells. Purified normal monocytes from different 
individuals (5 × 105 cells in culture medium with 10% fetal calf serum) 
were incubated for 3 days with or without a 20% concentration of RA 
ST cell culture supernatants, and IL-10R1 and IL-10R2 expression was 
analysed by flow cytometric analysis with anti-IL-10R1, anti-IL-10R2, 
and control antibodies. The induction of monocyte IL-10R1 and IL-
10R2 expression by supernatants was expressed by the ratio of the 
mean fluorescence intensity (MFI) of IL-10R expression with superna-
tants to the MFI without supernatants. Values are the mean ± standard 
error of the mean. n, number of samples tested.Arthritis Research & Therapy    Vol 8 No 4    Takasugi et al.
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however, TNFR2 expression was lower and M-CSFR expres-
sion was higher in the patients. Therefore, RA monocytes
appear to partially mature into the cells with high levels of IL-
10R1 and M-CSFR expression while in the blood circulation.
TNFR1 and TNFR2 induction in monocytes by IL-10 and 
M-CSF
Previous studies have demonstrated that IL-10 stimulates cell
surface expression of both TNF receptors, in particular TNFR2
on monocytes [20]. To confirm this finding, monocytes from
patients with RA and controls were incubated for 12 hours,
and TNFR1 and TNFR2 mRNA expression was measured by
real-time PCR. As shown in Figure 4, expression of both TNFR
receptors was augmented at the transcriptional level by IL-10.
RA monocytes were more responsive to IL-10 in terms of
TNFR2 induction than were normal monocytes, although
TNFR1 induction was weaker in RA monocytes.
IL-10 has been shown to enhance M-CSF-induced macro-
phage differentiation in part by M-CSFR upregulation [21].
Normal monocytes were incubated for 3 days with or without
M-CSF, IL-10, or IL-10 plus M-CSF, and their expression of M-
CSF and TNF receptors was analysed by flow cytometry. M-
CSFR expression was increased by IL-10 and, more signifi-
cantly, by IL-10 and M-CSF (Figure 5a). Accordingly, both
TNFR1 and TNFR2 expression was increased by IL-10 alone,
which was enhanced in the presence of M-CSF (Figure 5b,c).
These results indicate that cell surface expression of TNF
receptors on monocytes/macrophages may be effectively
increased by a combination of IL-10 and M-CSF.
TNF-α-induced cytokine production in monocytes 
preincubated with IL-10 and M-CSF
Preliminary culture experiments showed that TNF-α alone
failed to stimulate cytokine production by adhered monocytes.
In agreement with this finding, previous studies have demon-
strated that TNF-α could induce IL-1β production by mono-
cytes when intracellular cAMP levels were elevated by
Figure 3
Expression of type 1 and type 2 tumour necrosis factor receptor  (TNFR1/2) and macrophage colony-stimulating factor receptor (M- CSFR) on monocytes of patients with rheumatoid arthritis (RA) and  healthy controls (HCs) Expression of type 1 and type 2 tumour necrosis factor receptor 
(TNFR1/2) and macrophage colony-stimulating factor receptor (M-
CSFR) on monocytes of patients with rheumatoid arthritis (RA) and 
healthy controls (HCs). Peripheral blood mononuclear cells were 
stained with immunoglobulin (Ig) G2a anti-TNFR1 antibody, rabbit IgG 
anti-M-CSFR polyclonal antibody, or isotype-matched control antibody, 
followed by fluorescein isothiocyanate (FITC)-conjugated anti-mouse 
IgG2a antibody or phycoerythrin-conjugated anti-rabbit IgG antibody, 
and with FITC-conjugated anti-TNFR2 antibody. TNFR1, TNFR2, and 
M-CSFR expression on monocytes from patients with RA and HCs was 
analysed by flow cytometric analysis. The intensity of cytokine receptor 
was expressed by the ratio of the mean fluorescence intensity (MFI) of 
staining with anti-cytokine receptor antibody to the MFI of control anti-
body. Values are the mean ± standard error of the mean. n, number of 
samples tested.
Figure 4
Induction of mRNA expression of type 1 and type 2 tumour necrosis  factor receptor (TNFR1/2) in monocytes by interleukin-10 (IL-10) Induction of mRNA expression of type 1 and type 2 tumour necrosis 
factor receptor (TNFR1/2) in monocytes by interleukin-10 (IL-10). 
Adhered monocytes from patients with rheumatoid arthritis (RA) and 
healthy controls (HCs) (5 × 105 cells in culture medium with 10% fetal 
calf serum) were incubated for 12 hours with or without 25 ng/ml IL-10. 
Total cellular RNA was extracted from these monocytes, and mRNA 
expression was analysed by real-time polymerase chain reaction analy-
sis as described in Materials and methods. Levels of TNFR1 and 
TNFR2 mRNAs were normalised relative to β-actin expression, and the 
ratio of the levels of monocytes incubated with IL-10 to the levels with-
out IL-10 was determined. Values are the mean ± standard error of the 
mean. n, number of samples tested.Available online http://arthritis-research.com/content/8/4/R126
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Figure 5
Cytokine receptor induction on monocytes stimulated with interleukin-10 (IL-10) and macrophage colony-stimulating factor (M-CSF) Cytokine receptor induction on monocytes stimulated with interleukin-10 (IL-10) and macrophage colony-stimulating factor (M-CSF). (a) Induction of 
monocyte expression of M-CSF receptor (M-CSFR) by IL-10 and/or M-CSF. Purified normal monocytes from different individuals (5 × 105 cells in 
culture medium with 10% fetal calf serum) were incubated for 3 days with or without 50 ng/ml M-CSF, 25 ng/ml IL-10, or IL-10 plus M-CSF. M-
CSFR expression was analysed by flow cytometric analysis, and the cytokine-mediated M-CSFR induction was expressed by the ratio of the mean 
fluorescence intensity (MFI) of M-CSFR expression with cytokines to the MFI without cytokines. Values are the mean ± standard error of the mean. 
(b) Representative histographic patterns of type 1 and type 2 tumour necrosis factor receptor (TNFR1/2) expression on monocytes incubated with 
or without IL-10 plus M-CSF. TNFR1 and TNFR2 expression was analysed by flow cytometric analysis. (c) Induction of monocyte expression of 
TNFR1 and TNFR2 by IL-10 and/or M-CSF. The cytokine-mediated TNFR1/2 induction was expressed by the ratio of the mean fluorescence inten-
sity (MFI) of TNFR1/2 expression with cytokines to the MFI without cytokines. n, number of samples tested.Arthritis Research & Therapy    Vol 8 No 4    Takasugi et al.
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prostaglandin or in the presence of the cAMP analogue
dbcAMP and have proved a crucial role of cAMP signaling in
the activation of IL-1β gene transcription by site-directed
mutagenesis analysis of a CRE (cAMP response element) site
in the IL-1β promoter [27].
To assess the functional significance of increased TNF recep-
tor expression induced by IL-10 and M-CSF, normal mono-
cytes were preincubated for 3 days with or without M-CSF, IL-
10, or IL-10 plus M-CSF, then incubated for 24 hours with or
without TNF-α stimulation in the presence or absence of
dbcAMP, and their IL-1β and IL-6 production was measured
by ELISA. In the absence of dbcAMP, adhered monocytes
were unable to produce detectable amounts of cytokines in
response to TNF-α. Although the stimulatory effect of dbcAMP
alone was limited at a concentration of 30 µM, the combina-
tion of TNF-α and dbcAMP induced IL-1β and IL-6 production
by monocytes preincubated with M-CSF and, more promi-
nently, by monocytes with IL-10 and M-CSF (Figure 6). How-
ever, such cytokine production was rather diminished when
monocytes were preincubated with IL-10. These results sug-
gest that IL-10, despite its inhibitory potential, may facilitate
monocyte differentiation into TNF-α-responsive macrophages
in the presence of M-CSF by increasing surface TNF receptor
expression.
Expression of IL-10R1, M-CSFR, TNFR1, and TNFR2 in RA 
synovial lining macrophages
High levels of IL-10, M-CSF, and TNF-α expression have all
been detected in the inflamed joint of RA [14,23,28,29]. To
confirm the interaction of these cytokines in macrophage dif-
ferentiation at the site of inflammation, ST samples from five
patients with RA were analysed by two-color immunofluores-
cence labeling using Abs against IL-10R1, M-CSFR, and TNF
Figure 6
Tumour necrosis factor-α (TNF-α)-mediated interleukin (IL)-1β and IL-6 production by normal monocytes pretreated with IL-10 and/or macrophage  colony-stimulating factor (M-CSF) Tumour necrosis factor-α (TNF-α)-mediated interleukin (IL)-1β and IL-6 production by normal monocytes pretreated with IL-10 and/or macrophage 
colony-stimulating factor (M-CSF). Purified normal monocytes from different individuals were preincubated for 3 days with or without 50 ng/ml M-
CSF, 25 ng/ml IL-10, or IL-10 plus M-CSF and then stimulated for 24 hours with or without 10 ng/ml TNF-α, 30 µM dibutyryl cAMP (dbcAMP), or 
TNF-α plus dbcAMP. Concentrations of IL-1β and IL-6 in culture supernatants were measured in triplicate by the quantitative sandwich enzyme-
linked immunosorbent assay. Values are the mean ± standard error of the mean. n, number of samples tested.Available online http://arthritis-research.com/content/8/4/R126
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receptors, as well as anti-CD68 Ab. Figure 7 shows represent-
ative staining patterns in RA ST. The majority of M-CSFR+ and
IL-10R1+  cells were localised to the lining layer and the
endothelial cells, whereas TNFR1+ and TNFR2+ cells were
more widely distributed throughout the tissue, including the
lining layer and lymphocyte infiltrates. Colocalisation analysis
revealed that the CD68+ synovial lining layer contained a large
number of cells stained intensely for IL-10R1, M-CSFR, and
both TNF receptors, but such cells were sparsely distributed
in the sublining layer. Coexpression of these cytokine recep-
tors in lining macrophages suggests that costimulation with IL-
10 and M-CSF signals may be involved in the high expression
of TNF receptor in lining macrophages in the inflamed ST of
RA.
Microarray analysis of IL-10-induced gene expression in 
RA monocytes
To further elucidate the roles of IL-10 in monocyte maturation,
blood monocytes from two patients with RA were incubated
for 12 hours with or without IL-10 and the gene expression
profile was analysed by an microarray that detects 367 known
genes that encode for cytokines, chemokines and their recep-
tors, cell surface markers, representative signaling proteins,
and downstream targets of the signal transduction pathway.
Seventeen genes were identified as IL-10-inducible (> twofold
increase in gene expression) in both patients with RA,
although a total of 87 gene signals were increased by IL-10 in
either patient. As shown in Table 2, these genes include the
TNF receptor superfamily, chemokine receptors, growth factor
receptors, TLRs, and TNF receptor-associated factors
(TRAFs), although it also induced the endogenous JAK (Janus
kinase) kinase inhibitor SOCS (suppressor of cytokine signal-
ing) 3, as has previously been described [30]. Thus, IL-10 can
activate various genes essential for macrophage functions.
Discussion
IL-10, known as a potent inhibitor for the synthesis of proin-
flammatory cytokines in monocytes/macrophages and T cells
[11], is substantially expressed by lining macrophages and
infiltrating T cells in the inflamed ST of RA [13,14]. Studies of
RA ST cell cultures indicated that IL-10 may be relatively defi-
cient as compared with proinflammatory cytokines in the joint
[13,15], and IL-10 has been protective in animal models of
arthritis [16,17], which suggested its therapeutic potential in
human RA. However, clinical studies using human rIL-10 have
so far failed to prove its potent anti-inflammatory effects in
patients with RA [16-18]. Thus, IL-10 may be an important par-
ticipant of the complex cytokine network of RA, also playing a
proinflammatory role in joint inflammation.
In the present study, we demonstrated that blood monocytes
from patients with RA express high levels of IL-10R1 and M-
CSFR, but not of TNF receptors, and that their TNFR1 and
TNFR2 expression is effectively augmented by a combination
of IL-10 and M-CSF. Monocytes preincubated with IL-10 and
M-CSF are able to respond to TNF-α stimulation by producing
IL-1β and IL-6. IL-10R1, M-CSFR, and both types of TNF
receptor are all intensively expressed in CD68+ macrophages
localised to the lining layer in RA ST. These results suggest
that IL-10 may contribute to M-CSF-induced monocyte differ-
entiation into the proinflammatory type of macrophages by
increasing TNF receptors in RA, which is thought to partly
explain the poor clinical efficacy of IL-10 therapy in the
patients.
Figure 7
Expression of type 1 interleukin-10 receptor (IL-10R1), macrophage  colony-stimulating factor receptor (M-CSFR), and type 1 and 2 tumour  necrosis factor receptor (TNFR1/2) in synovial tissue (ST) from patients  with rheumatoid arthritis Expression of type 1 interleukin-10 receptor (IL-10R1), macrophage 
colony-stimulating factor receptor (M-CSFR), and type 1 and 2 tumour 
necrosis factor receptor (TNFR1/2) in synovial tissue (ST) from patients 
with rheumatoid arthritis. ST sections were stained with mouse immu-
noglobulin (Ig) G1 anti-IL-10R1 monoclonal antibody (mAb), rabbit IgG 
anti-TNFR1 Ab, rabbit IgG anti-TNFR2 Ab, rabbit IgG anti-M-CSFR Ab, 
mouse IgG1 anti-CD68 mAb, and isotype-matched control Abs, fol-
lowed by incubation with rhodamine-conjugated goat anti-mouse IgG1 
mAb and fluorescein isothiocyanate-conjugated anti-rabbit IgG mAb. 
Two-color immunofluorescence confocal images were obtained for 
expression of IL-10R1 (red staining), M-CSFR (red), TNFR1 (green), 
TNFR2 (green), and CD68 (green). The two images were superim-
posed, and double-positive cells are shown in yellow. Similar staining 
patterns were obtained in additional analyses from five ST samples 
from different patients.Arthritis Research & Therapy    Vol 8 No 4    Takasugi et al.
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Table 2
Major interleukin-10 (IL-10)-induced transcripts in monocytes from patients with rheumatoid arthritis
Symbol Encoded protein Gene name IL-10-induced changes (folds)
Patient 1 Patient 2
BMPR1A Bone morphogenetic protein receptor, type IA ALK-3 2.41 2.37
BMPR1B Bone morphogenetic protein receptor, type IB ALK-6 0.74 9.79
BMPR2 Bone morphogenetic protein receptor, type II BMPR-II 1.81 1.32
CCL15 Chemokine (C-C motif) ligand 15 MIP-1 delta/MIP-
5
1.84 1.07
CCR5 Chemokine (C-C motif) receptor 5 CCR5 1.93 1.11
CXCL3 Chemokine (C-X-C motif) ligand 3 GRO3 2.17 0.83
IRAK2 Interleukin-1 receptor-associated kinase 2 IRAK2 1.93 2.73
SOCS3 Suppressor of cytokine signaling 3 SSI-3 3.84 15.29
TGFBR2 Transforming growth factor, β receptor II TGFBR2 2.17 0.79
TGFBR3 Transforming growth factor, β receptor III TGFBR3 2.04 0.29
TIMP1 Tissue inhibitor of metalloproteinase 1 TIMP1 3.49 1.46
TLR2 Homo sapiens Toll-like receptor 2 TLR2 1.38 2.28
TLR3 Homo sapiens Toll-like receptor 3 TLR3 3.03 16.61
TLR4 Homo sapiens Toll-like receptor 4 TLR4 2.66 1.86
TLR9 Homo sapiens Toll-like receptor 9 TLR9 2.44 0.78
TLR10 Homo sapiens Toll-like receptor 10 TLR10 2.78 0.90
TNFRSF1B Tumour necrosis factor receptor superfamily, member 1B TNFR2/p75 2.64 0.91
TNFRSF7 Tumour necrosis factor receptor superfamily, member 7 CD27 8.99 0.57
TNFRSF8 Tumour necrosis factor receptor superfamily, member 8 CD30 3.13 1.15
TNFSF11 Tumour necrosis factor (ligand) superfamily, member 11 TRANCE 3.50 2.01
TNFRSF11A Tumour necrosis factor receptor superfamily, member 11a, 
activator of nuclear factor-κB
Rank 2.50 0.56
TNFSF4 Tumour necrosis factor (ligand) superfamily, member 4 OX40L 2.67 1.06
TRAF4 TNF receptor-associated factor 4 TRAF4 2.18 1.00
TRAF6 TNF receptor-associated factor 6 TRAF6 3.49 0.56
PUC18 PUC18 plasmid DNA pUC18 0.00 0.00
ACTB β-actin β-actin 0.92 0.91Available online http://arthritis-research.com/content/8/4/R126
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In association with joint inflammation, blood monocytes
become activated before entry into the joint in RA. We have
previously demonstrated that CD16-expressing mature mono-
cytes – a subpopulation of cells that, while in the circulation,
has acquired features in common with proinflammatory tissue
macrophages – are expanded in patients with active disease.
CD16+ monocytes can rapidly migrate to the site of inflamma-
tion through high-level expression of adhesion molecules and
chemokine receptors. The maturation of CD16+ monocytes
could be induced by a spillover effect of cytokines produced
in the inflamed ST, most notably M-CSF and IL-10 [22,23]. IL-
10R1 expression plays a critical role in cellular responses to
IL-10 [31]. We found that IL-10R1 expression on monocytes
was increased according to the disease activity in patients
with RA, as defined by the DAS system, and that the IL-10R1
expression was augmented in the presence of RA ST cell cul-
ture supernatants, which indicates that IL-10R1 upregulation
may be associated with monocyte maturation induced by RA
synovial inflammation. In addition, M-CSFR expression was
found to be increased in RA monocytes. Therefore, such acti-
vated expression of both IL-10R1 and M-CSFR appears to be
involved in CD16+ monocyte maturation.
M-CSF, although originally identified as a hematopoietic
growth factor of macrophage-lineage cells, stimulates the sur-
vival, proliferation, and differentiation into macrophages and
osteoclasts of monocytes and activates their functions such
as cytokine production [32]. The involvement of M-CSF in RA
pathogenesis has been suggested by in vivo studies of colla-
gen-induced arthritis [33]. In this murine model of autoimmune
arthritis, M-CSF administration exacerbated disease symp-
toms, neutralisation of endogenous M-CSF with Ab reduced
the disease severity, and M-CSF-deficient mice (op/op)
showed no chronic arthritis. In RA joints, high levels of M-CSF
have been detected [23,34,35], and the cellular source of this
proinflammatory cytokine includes synovial fibroblasts,
chondrocytes, and tissue macrophages [34,36-38]. In partic-
ular, synovial fibroblasts constitutively produce M-CSF, and
their production is believed to be markedly increased in the
cytokine milieu, where potent stimulators such as TNF-α and
IL-1 are abundant [1,36,38].
Higher levels of IL-10R1 and M-CSFR were expressed on
monocytes from patients with RA as compared with healthy
controls, but their expression of both TNFR1 and TNFR2 was
not increased. By two-color immunofluorescence labeling of
RA ST samples, synovial lining macrophages were found to
strongly express both types of TNF receptor, as well as IL-
10R1 and M-CSFR. Macrophages accumulating in the lining
layer represent the highly activated phenotype of this lineage,
as evidenced by high levels of cell surface expression of
CD16, CD68, major histocompatibility complex class II anti-
gens, and various adhesion molecules, and by overproduction
of the essential proinflammatory cytokines TNF-α and IL-1β
[39]. We found that expression of both TNF receptors in
monocytes was increased by IL-10 stimulation, and more effi-
ciently in combination with M-CSF, and that in vitro differenti-
ated macrophages in the presence of IL-10 and M-CSF could
respond to TNF-α stimulation by inducing other cytokines
such as IL-1β and IL-6. Therefore, monocytes with high-level
expression of IL-10R1 and M-CSFR may readily differentiate
into TNF-α-responsive macrophages in the inflamed joint,
where these receptor ligands are produced at high levels. In
this regard, RA monocytes are thought to be undergoing mat-
uration into macrophages before entry into the joints.
IL-10 may not be a general inhibitor of inflammatory responses
in RA, but rather a stimulator in terms of monocyte differentia-
tion. In addition to its induction of TNF receptors, IL-10 has
been shown to potentiate immune complex-mediated proin-
flammatory responses and tissue destruction by stimulating
FcγRI and FcγRII expression on monocytes [18]. Such IL-10
induction of inflammatory molecules in monocytes/macro-
phages was confirmed by our microarray analysis of gene
expression showing that IL-10 activated various genes essen-
tial for macrophage functions, including other members of the
TNF receptor superfamily, receptors for chemokines and
growth factors, TLRs, and TRAFs. Furthermore, most of the IL-
10 effects on B-cell function are stimulatory. IL-10 has been
implicated in the maturation of B cells into plasma cells in the
presence of synovial fibroblasts from RA [40], the spontane-
ous IgM-RF production by B cells [41], and the Th2 cell-medi-
ated B-cell Ig production [29]. These B-cell stimulatory effects
of IL-10 could be important in the perpetuation of RA inflam-
mation because an inflammatory role of B cells in the patho-
genesis has recently been supported by clinical efficacy of B-
cell depletion therapy with anti-CD20 Ab in patients with RA
resistant to TNF-α inhibitors [42]. It would therefore seem that
the positive effects of IL-10 on macrophage and B-cell matu-
ration may neutralise its otherwise anti-inflammatory properties
in RA, as has been shown by clinical studies [17,18].
Conclusion
Blood monocytes from patients with RA express high levels of
IL-10R1 and M-CSFR in association with joint inflammation,
and their TNFR1 and TNFR2 expression is effectively aug-
mented by a combination of IL-10 and M-CSF. Monocytes pre-
incubated with IL-10 and M-CSF are able to respond to TNF-
α stimulation by producing IL-1β and IL-6. Receptors for IL-10,
M-CSF, and TNF-α are all intensively expressed by lining
CD68+ macrophages in the ST lesion of RA. Therefore, IL-10
may play an important role in M-CSF-induced monocyte differ-
entiation into TNF-α-responsive macrophages by increasing
TNF receptors in RA joints.
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